<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d1 20130915//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.1d1">
  <front>
    <journal-meta>
      <journal-title-group>
        <journal-title>Biomedical Research and Therapy</journal-title>
      </journal-title-group>
      <issn pub-type="epub" publication-format="electronic">2198-4093</issn>
      <publisher>
        <publisher-name>BioMedPress</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="doi">10.15419/bmrat.v4i05.169</article-id>
      <article-categories>
        <subj-group subj-group-type="display-channel">
          <subject>Research Article</subject>
        </subj-group>
        <subj-group subj-group-type="heading">
          <subject>Biomedical Research and Therapy</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Haloperidol induced Parkinson&#8217;s disease mice model and motor-function modulation with Pyridine-3-carboxylic acid</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Saeed</surname>
            <given-names>Atif</given-names>
          </name>
          <xref ref-type="aff" rid="aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Shakir</surname>
            <given-names>Lubna</given-names>
          </name>
          <xref ref-type="aff" rid="aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>A. Khan</surname>
            <given-names>Mahtab</given-names>
          </name>
          <xref ref-type="aff" rid="aff2"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Ali</surname>
            <given-names>Arsalan</given-names>
          </name>
          <xref ref-type="aff" rid="aff1"/>
        </contrib>
        <contrib contrib-type="author" corresp="yes">
          <name>
            <surname>Yousaf</surname>
            <given-names>Muhammad</given-names>
          </name>
          <xref ref-type="aff" rid="aff1"/>
          <xref ref-type="corresp" rid="cor1">*</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Ali Zaidi</surname>
            <given-names>Awais</given-names>
          </name>
          <xref ref-type="aff" rid="aff2"/>
        </contrib>
        <aff id="aff1">
          <institution>Faculty of Pharmacy, Hajvery University, Lahore-Pakistan</institution>
        </aff>
        <aff id="aff2">
          <institution>Faculty of Pharmacy, The University of Lahore, Lahore-Pakistan</institution>
        </aff>
      </contrib-group>
      <author-notes>
        <corresp id="cor1"><label>*</label>For correspondence: <email>dr.yousaf_muhammad@yahoo.com</email></corresp>
        <fn fn-type="con" id="equal-contrib">
          <label>*</label>
          <p>These authors contributed equally to this work</p>
        </fn>
      </author-notes>
      <pub-date date-type="pub" publication-format="electronic">
        <day>22</day>
        <month>05</month>
        <year>2017</year>
      </pub-date>
      <volume>4</volume>
      <issue>5</issue>
      <fpage>1</fpage>
      <lpage>3</lpage>
      <history>
        <date date-type="received">
          <day>02</day>
          <month>03</month>
          <year>2017</year>
        </date>
        <date date-type="accepted">
          <day>01</day>
          <month>05</month>
          <year>2017</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>Copyright: &#169; The Author(s) 2017</copyright-statement>
        <copyright-year>2017</copyright-year>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/CC-BY/4.0">
          <license-p>This article is published with open access by BioMedPress (BMP), Laboratory of Stem Cell Research and Application, Vietnam National University, Ho Chi Minh city, Vietnam This article is distributed under the terms of the Creative Commons Attribution License (CC-BY 4.0) which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.</license-p>
        </license>
      </permissions>
      <self-uri content-type="pdf" xlink:href="http://www.bmrat.org/index.php/BMRAT/article/view/169/496"/>
      <abstract>
        <p>Introduction: Motor-function modulation through Pyridine-3-carboxylic acid was assessed against. Haloperidol induced Parkinson&#8217;s disease (PD) in albino-mice. The objectives of this study were to test the effect of Haloperidol in development of PD, effectiveness of Pyridine-3-carboxylic acid in mice and evaluation of the motor-function changes in mice before and after treatment.</p>
        <p>Methods: The study was divided into 3 phases: During Phase-I (randomization), all the subjects were randomly divided into 4 groups and trained for wire-hanging, grip strength, vertical rod and swim tests for 1 week. During Phase-II (disease induction), PD was induced by intra-peritoneal (ip) administration of Haloperidol (HP) in a dose of 1 mg/kg/d for 7 days. Group-A comprised of healthy controls, Group-B (Diseased), Group-C (HP+Pyridine-3-carboxylic acid 7.15 mg/kg/d) and Group-D (HP+Pyridine-3-carboxylic acid15 mg/kg/d).</p>
        <p>Results: Pyridine-3-carboxylic acid treatment continued for 5 weeks. During Phase-III the above mention tests were performed and the effects of Pyridine-3-carboxylic acid were recorded. However, in swim test Group D is statistically insignificant as compared to Group B (p=0.284). In recent study, haloperidol is found to be effective in inducing motor function anomalies likewise in Parkinson&#8217;s disease including movement slowness, difficulties with gait and balance.</p>
        <p>Conclusion: oral administration of Pyridine-3-carboxylic acid improved Motor-function changes in diseased mice. Therefore, it is concluded that Pyridine-3-carboxylic acid may help to alleviate PD symptoms.</p>
      </abstract>
      <kwd-group>
        <kwd>Pyridine-3-carboxylic acid</kwd>
        <kwd>Haloperidol</kwd>
        <kwd>motor-function modulation</kwd>
        <kwd>Parkinson&#8217;s disease</kwd>
        <kwd>Mice</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec id="s1">
      <title>Introduction</title>
      <p>Parkinson&#8217;s disease (PD) was first illustrated by James Parkinson in 1817 in &#8220;An Essay on the Shaking Palsy&#8221; <xref ref-type="bibr" rid="ref10">Kempster et al., 2007</xref>. The major symptoms of PD are tremors, bradykinesia, postural instability and rigidity, postural abnormalities, akinesia and festinating gait. These symptoms are led by psychological symptoms such as depression and more general non-motor symptoms such as olfactory dysfunction constipation, and sleep disturbances <xref ref-type="bibr" rid="ref12">Klockgether, 2004</xref>. The incidence of Parkinson&#8217;s disease (PD) is nearly about 1% at the age of 65 years which further increased to 5% with the age of 85 years <xref ref-type="bibr" rid="ref9">Hirtz et al., 2007</xref>. Haloperidol is a typical neuroleptic drug and shows effect by blocking the postsynaptic dopamine D<sub>2</sub> receptors in the mesolimbic system and cause an escalation of dopamine turnover by blockage of the D<sub>2</sub> receptors <xref ref-type="bibr" rid="ref24">Zaidi et al., 2016a</xref>. Anticholinergic and &#946;-adrenergic receptor blocking effects of haloperidol is quite weak. Parkinson disease is characterized majorly by the loss of melanin containing dopaminergic neurons in zona compacta of the substantia nigra <xref ref-type="bibr" rid="ref2">Bernheimer et al., 1973</xref>. Haloperidol causes a decrease in dopamine neurotransmission <xref ref-type="bibr" rid="ref17">Naidu et al., 2003</xref>. Haloperidol exerts its antipsychotic effect most likely through potent blockade of central dopamine receptors and marked rigidity linked with haloperidol administration <xref ref-type="bibr" rid="ref25">Zaidi et al., 2016b</xref>. In animal studies, neurotoxins such as 1-methyl-4-phenyl-1,2,3,6-tetrahydroxypyridine (MPTP) and 6-OHDA and haloperidol are used commonly to create experimental model of PD <xref ref-type="bibr" rid="ref7">Fernagut et al., 2002</xref><xref ref-type="bibr" rid="ref22">Sheidaei, 2010</xref> by which certain aspects of the disease such as motor abnormalities and slowing and of movement and catalepsy can be modeled <xref ref-type="bibr" rid="ref21">Scholtissen et al., 2006</xref><xref ref-type="bibr" rid="ref23">Wang et al., 2005</xref>. Clinical symptoms appear only when dopaminergic neuronal death exceeds a critical threshold 70-80% of striatal nerve terminals.</p>
      <p>Vitamin B<sub>3</sub> also known as Pyridine-3-carboxylic acid and found in foods including certain types of meat and organ meat, tuna fish, seeds, mushrooms and others. Vitamin B<sub>3</sub>, which is usually medically referred to as Pyridine-3-carboxylic acid, comes in 3 forms nicotinic acid, Pyridine-3-carboxylic acid amide and Inositol HexaPyridine-3-carboxylic acidate. Vitamin B<sub>3</sub> Pyridine-3-carboxylic acid has been studied extensively to treat of many commonly occurring health problems. Pyridine-3-carboxylic acid is an important vitamin for maintaining healthy brain function and healthy cardiovascular system and metabolism, especially balancing blood cholesterol levels <xref ref-type="bibr" rid="ref8">Gurakar et al., 1985</xref><xref ref-type="bibr" rid="ref16">Morris et al., 2004</xref>. Nicotinic acid (Pyridine-3-carboxylic acid) has shown neuro-protective role in mice-stroke model by promoting the monocyte polarization into protective phenotype in brain (Rahman et al., 2014). Absorbed niacin is used in the synthesis of nicotinamide adenine dinucleotide (NAD) in the body, and in the metabolic process NAD releases nicotinamide by poly ADP-ribosylation, the activation of which has been reported to mediate 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinson&#8217;s disease <xref ref-type="bibr" rid="ref15">Molina et al., 1996</xref>.</p>
      <p>The objectives of this study were to evaluate the effect of Haloperidol in development of PD, effectiveness of Pyridine-3-carboxylic acid to modulate Motor-function activities in mice model PD and record the Motor-function changes in mice before &amp; after the treatment of PD with Pyridine-3-carboxylic acid.</p>
    </sec>
    <sec id="s2">
      <title>Materials - Methods</title>
      <sec id="s2-1">
        <title>Study design</title>
        <p>Albino mice (20-25g) were taken from animal house of UVAS (University of veterinary sciences, Lahore-Pakistan). The animals were acclimatized and kept under specified temperature (22&#177;2&#176;C) and humidity (60&#177;2%) under 12-hours light/dark cycles with food and water ad libitum. Experimental procedures and animal handling were approved by Institutional Committee of Research Ethics, Hajvery University (Ethical no. 720EN-2016) Lahore, Pakistan.</p>
        <p>The study was divided into three phases. <xref ref-type="fig" rid="tab1"> Table 1 </xref> </p>
        <fig id="tab1">
          <label>Table 1</label>
          <caption>
            <p>Experimental layout of this study</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="bmrat.v4i05.169/tab1.png"/>
        </fig>
      </sec>
      <sec id="s2-2">
        <title>Phase-I</title>
        <p>During Phase-I, the motor-function modeling of mice was performed using wire hanging test, grip strength test, vertical rod test, and swim test. All subjects were trained and divided into four groups comprising of 7 mice in each.</p>
        <p>Wire Hanging Test</p>
        <p>The wire hanging test was used to assess muscle function and coordination over time. The test is based on the latency of a mouse to fall off a metal wire upon exhaustion. The wire hanging test is performed in order to demonstrate a motor neuromuscular impairment and motor coordination. This test was also used for evaluating the neuromuscular tone. A 55 cm wide 2 mm thick wire is secured to two vertical stands. The wire must be tightly attached to the frame to avoid vibration or unwanted displacement of the wire while the investigator is handling the animals or during the measurements, since these unwanted effects would interfere with the animal&#8217;s performance <xref ref-type="bibr" rid="ref1">Aartsma-Rus and van Putten, 2014</xref><xref ref-type="bibr" rid="ref11">Klein and Lewis, 2012</xref>.</p>
        <p>Grip Strength Test</p>
        <p>The grip strength test is a modest non-intrusive method intended to assess mouse muscle power in vivo, by taking benefit of the animal's affinity to grip a flat metal bar or framework while suspended by its tail or each of the four appendages. This is a pure test of strength, although as for any test motivational factors could potentially play a role. The inverted screen is a 43 cm square of wire mesh consisting of 12 mm squares of 1 mm diameter wire. We place the mouse in the center of the wire mesh screen, start a stop clock, and rotate the screen to an inverted position over 2 sec, with the mouse's head declining first. We hold the screen steadily 40-50 cm above a padded surface.</p>
        <p>Vertical Pole Test</p>
        <p>Vertical pole test is used to measure the sensorimotor function of mice. PD motor tests provide a good read-out of neurological function.. Each mouse is placed head upwards at the centre of a round pole that is inclined at 90&#176; and performance is determined by the latency(s) of the mouse to turn downwards and completely descend the pole. In a habituation period one day prior to testing, each mouse is allowed to attempt to descend the pole. Each testing session lasts for a maximum of 180 seconds.</p>
        <p>Swim Test</p>
        <p>The forced swim test, also known as the behavioral despair test, is used to test for depression-like behavior in both mice and rats. The test includes placing a rat or mouse inside a cylinder filled with water. The mobility of the animal is measured. Traditionally, &#8216;floating behavior&#8217; (the animal remains almost immobile and with its head above water). The forced swim test is a mice Motor-function test utilized for assessment of stimulant medications, upper adequacy of new mixes, and trial controls that are gone for rendering or anticipating depressive-like states</p>
      </sec>
      <sec id="s2-3">
        <title>Phase-II</title>
        <p>During Phase-II, PD was induced by administering Haloperidol of 1mg / kg per day (ip) for 7 days. All animals were observed for 30 minutes post injection and then hourly intervals for next 3 hours. At the end of the 7th day, PD was assessed by hind limb movements and behavior <xref ref-type="bibr" rid="ref14">Manikandaselvi et al., 2012</xref>. After induction of disease, subjects were divided into four groups. Group A (Normal) containing normal mice with (i.p) injection of saline served as control. Group B served as diseased group received (i.p) injection of haloperidol (1 mg/kg per day) for seven days. Group C and D were administered Pyridine-3-carboxylic acid orally, 7.15 mg and 15 mg per kg of body weight orally for 36 days respectively.</p>
      </sec>
      <sec id="s2-4">
        <title>Phase-III</title>
        <p>During Phase-III, following four tests were performed on daily basis to check the difference in behavior before induction of PD and after treatment. These tests include wire hanging test, grip strength test, Vertical rod test, and swim test <xref ref-type="bibr" rid="ref24">Zaidi et al., 2016a</xref>.</p>
        <p>Statistical Analysis</p>
        <p>Data was statistically analyzed on SPSS version 22.0 using ANOVA with a p &lt; 0.05 considered as significant.</p>
      </sec>
    </sec>
    <sec id="s3">
      <title>Results</title>
      <p>The present study was conducted to assess the neuro-protective and motor-function modulation activity of Pyridine-3-carboxylic acid in HP induced PD animal model. Mice were acclimatized and their Motor-function modeling was done. Following four tests were applied to mice. These are swim test, vertical pole, grip strength, and wire hanging test. During these tests, physical and social activities of the mice were monitored.</p>
      <sec id="s3-1">
        <title>Wire Hanging Test</title>
        <p>During motor-function modulation, an important parameter for treatment effectiveness is neuromuscular strength. Wire hanging test was performed to assess the neuromuscular ability of mice. While performing this test, animal were suspended by its fore paws with a 2 mm wire 30 cm above the ground. By performing this test, the measure of motor coordination and animal&#8217;s ability to take on its hind limbs and tail with a specific end goal to grasp wire was observed. Latency to fall was measured from the time a mouse hanged by its forepaws till it falls. The test was performed five times for each mouse and a mean value was considered and analyzed by one way ANOVA. It was observed during experimentation that Group D showed more neuromuscular strength than Group C as shown in <xref ref-type="fig" rid="fig1"> Figure 1 </xref>. However, results of group D were not statistically much significant (P=0.082) in comparison with Group C.</p>
        <fig id="fig1">
          <label>Figure 1</label>
          <caption>
            <title>Wire hanging test</title>
            <p>It was observed during experimentation that Group D showed more neuromuscular strength than Group C as shown in However, results of group D were not statistically much significant (P=0.082) in comparison with Group C.</p>
          </caption>
          <graphic xlink:href="bmrat.v4i05.169/fig1.png"/>
        </fig>
      </sec>
      <sec id="s3-2">
        <title>Grip Strength Test</title>
        <p>The modified screen is a 43 cm square of wire cross section comprising of 12 mm squares of 1 mm measurement wire. It is encompassed by a 4 cm profound wooden beading which keeps the infrequent mouse which endeavors to from hopping on to the next side. It is a test of muscle quality utilizing each of the four  appendages.  Most  ordinary  mice  effortlessly  score  greatest  on  this undertaking; it is a brisk yet heartless gross screen. A common error with commercial strength meters is that the bar or other grip feature is not thin enough for mice to exert a maximum grip. As a general rule, the thinner the wire or bar, the better a mouse can grip with its small claws.</p>
        <p>Another key feature for treatment effectiveness is neuromuscular strength. This is an  immaculate  test  of  quality,  despite  the  fact  that  concerning  any  test motivational variables could conceivably assume a part. Grip strength test showed that Group D mice had strong grip as compared to Group C and Group B mice as shown in <xref ref-type="fig" rid="fig2"> Figure 2 </xref>. Results were found statistically significant for Group D in comparison with Group C (P=0.047). It was also observed during study that Group  B  had  shown  least  strength  of  grip  than  Group  A  (P=0.005)  as demonstrated in <xref ref-type="fig" rid="fig2"> Figure 2 </xref>.</p>
        <fig id="fig2">
          <label>Figure 2</label>
          <caption>
            <title>Grip strength test</title>
            <p>It showed that Group D mice had strong grip as compared to Group C and Group B mice as shown in Results were found statistically significant for Group D in comparison with Group C (P=0.047). It was also observed during study that Group B had shown least strength of grip than Group A (P=0.005).</p>
          </caption>
          <graphic xlink:href="bmrat.v4i05.169/fig2.png"/>
        </fig>
      </sec>
      <sec id="s3-3">
        <title>Vertical Pole Test</title>
        <p>This test is used to measure the sensorimotor function of mice. PD motor tests provide a good read-out of neurological function. In case of Group D, it was seen that this group was statistically insignificant than Group B (P=0.409) while it was also noted that this group showed better neurological function as compared to Group C. However, results were also found insignificant for Group C as compared to Group B (P=1.00). <xref ref-type="fig" rid="fig3"> Figure 3 </xref></p>
        <fig id="fig3">
          <label>Figure 3</label>
          <caption>
            <title>Vertical pole test</title>
            <p>In case of Group D, it was seen that this group was statistically insignificant than Group B (P=0.409) while it was also noted that this group showed better neurological function as compared to Group C.</p>
          </caption>
          <graphic xlink:href="bmrat.v4i05.169/fig3.png"/>
        </fig>
      </sec>
      <sec id="s3-4">
        <title>Swim Test</title>
        <p>The forced swim test is a rat Motor-function test utilized for assessment of stimulant medications, upper adequacy of new mixes, and trial controls that are gone for rendering or anticipating depressive-like states.</p>
        <p>In case of Swim Test, Group D is statistically insignificant in association with Group C (P=0.284) and Group B (P=0.221). Therefore, it was observed that results were not statistically significant among all four groups in case of swim test as demonstrated in <xref ref-type="fig" rid="fig4"> Figure 4 </xref>. Consequently in our study, it was observed that Pyridine-3-carboxylic acid 15 mg/kg/day PO dose is found effective as compared to Pyridine-3-carboxylic acid 7.15 mg/kg/day PO dose.</p>
        <fig id="fig4">
          <label>Figure 4</label>
          <caption>
            <title>Swim test</title>
            <p>In case of Swim Test, Group D is statistically insignificant in association with Group C (P=0.284) and Group B (P=0.221). Therefore, it was observed that results were not statistically significant among all four groups</p>
          </caption>
          <graphic xlink:href="bmrat.v4i05.169/fig4.png"/>
        </fig>
      </sec>
    </sec>
    <sec id="s4">
      <title>Discussion</title>
      <p>The principle objective of exploration study displayed in this postulation is to describe the impacts of HP in the improvement of PD models and Motor-function  undertakings  some  time  recently,  amid,  and  after  treatment  with Pyridine-3-carboxylic  acid.  In  the  present  study,  HP  treatment  altogether expanded vacuous biting development and tardive dyskinesia when contrasted with control mice. Neuroleptics act by blocking dopamine receptors <xref ref-type="bibr" rid="ref5">Creese et al., 1976</xref>. Such blockage results in expanded dopamine turnover, which thus prompts expanded generation of hydrogen peroxide, bringing about oxidative anxiety <xref ref-type="bibr" rid="ref4">Chauhan et al., 2004</xref><xref ref-type="bibr" rid="ref6">Elkashef and Wyatt, 1999</xref>. Existing proof shows that  inordinate  creation  of  free  radicals  is  connected  with  interminable neuroleptic utilize and may add to the onset of tardive dyskinesia and other development issue, for example, dystonias and Parkinsonism <xref ref-type="bibr" rid="ref3">Burger et al., 2005</xref>.</p>
      <p>During  motor-function  modulation,  an  important  parameter  for  treatment effectiveness is neuromuscular strength. Wire hanging test was performed to assess  the  neuromuscular  ability  of  mice.  It  was  observed  during experimentation that Group D showed more neuromuscular strength than Group C as shown in <xref ref-type="fig" rid="fig1"> Figure 1 </xref>. However, results of group D were not statistically much significant (P=0.082) in comparison with Group C. In one of the study where Effect of hypericum hookeranium on HP induced neuromuscular weakness was tested by wire hang test. Less latency to fall by releasing the wire soon indicates the apathetic state in the induced animal. The latency in falling represent the improved neuromuscular strength in 400 mg/kg EEHH treated animals with the same effect as that of the standard drug scopolamine. Before treatment animals had excellent neuromuscular activity, reduced by the treatment of Haloperidol. hypericum hookeranium at the dose 400mg/kg significantly <xref ref-type="bibr" rid="ref19">Pongiya et al., 2014</xref>.  The  effect  of  low  doses  of  Pyridine-3-carboxylic  acid  show  more promising effects as compared to hypericum hookeranium 400mg/kg in this study.</p>
      <p>Grip strength test is a test of muscle strength using all fore limbs. However, in our research study, Grip strength test showed that Group D mice had strong grip as compared to Group C and Group B mice as shown in <xref ref-type="fig" rid="fig2"> Figure 2 </xref>. Results were found statistically significant for Group D in comparison with Group C (P=0.047). It was also observed during study that Group B had shown least strength of grip than Group A (P=0.005) as demonstrated in <xref ref-type="fig" rid="fig2"> Figure 2 </xref>. The dose of 15mg/kg on HP induced mice model of PD show more promising effects during grip strength test as compared to 7.15 mg/kg. In one of the study, same tests were applied on mice model to check the impacts of HP on hold quality test are outlined at the lower left partition. There was a measurably huge general treatment impact and a pattern toward expanded grasp quality in the haloperidol-induced mice when subjected to motor integration tests. Grip strength test showed a decrease in muscle  coordination  which  could  be  due  to  a  loss  of  muscular  strength.</p>
      <p>Treatment  with  MECD  showed  a  significant  improvement  in  the  muscle coordination as there is an increase in retention time and fall-off time in grip strength  test  respectively.  Locomotor  activity  was  also  studied  using actophotometer in which MECD improved the photocells count which was significantly less in HP treated group <xref ref-type="bibr" rid="ref18">Pavan et al., 2015</xref>.</p>
      <p>Vertical pole test is used to measure the sensorimotor function of mice. PD motor tests provide a good read-out of neurological function. The vertical pole test provides the information about the level of catalepsy generated by HP in mice model of PD and its effects on mice during and after the treatment on vertical pole test. In one of the study, HP created the prolongation of T-turn and TLA as a marker of bradykinesia in mice and the prolongation kept going no less than 7 hr after HP treatment. Intraperitoneal co-pretreatment with L-DOPA (400 mg/kg) + carbidopa (10 mg/kg) in mice diminished the catalepsy instigated by HP at a measurements of 0.125 mg/kg, while co-pretreatment with L-DOPA (200 and 400 mg/kg) + carbidopa (10 mg/kg) dosage conditionally diminished the HP (0.125 mg/kg) actuated bradykinesia. The impact of LDOPA + carbidopa in post-test was more purported than that in catalepsy test <xref ref-type="bibr" rid="ref13">Kobayashi et al., 1997</xref>. The treatment with Pyridine-3-carboxylic acid in our research study show significant results in mice model of PD. In case of Group D, it was seen that this group was statistically insignificant than Group B (P=0.409) while it was also noted that this group showed better neurological function as compared to Group C. However, results were also found insignificant for Group C as compared to Group B (P=1.000). The data show that the both doses of Pyridine-3-carboxylic acid did not put much influence in this analytical parameter.</p>
      <p>The  forced  swim  test  were  utilized  for  assessment  of  upper  medications, energizer viability of new mixes, and trial controls that are gone for rendering or counteracting depressive-like states. In one of the research study, swim test was used to evaluate the effectiveness of S-acetylcysteine on HP induced mice model of PD. In case of Swim Test, Group D is statistically insignificant in association with Group C (P=0.284) and Group B (P=0.221). Therefore, it was observed that results were not statistically significant among all four groups in case of swim test as demonstrated in figure 4. Consequently, in our study, it was observed that Pyridine-3-carboxylic acid15mg/kg/day PO dose is found effective as compared to Pyridine-3-carboxylic acid7.15mg/kg/day PO dose..</p>
    </sec>
    <sec id="s5">
      <title>Conclusion</title>
      <p>In the present study, the activities of mice get reduced after the administration of haloperidol due to its effect on dopamine blockade and development of symptoms of PD and Motor-function changes. The findings of the present study suggested that the use of Pyridine-3-carboxylic acid may be helpful as an adjunct therapy with standard therapy of Levodopa/Carbidopa in PD patients and can also decrease the level of association of free radicals in the improvement of neuroleptic prompted PD.</p>
    </sec>
    <sec id="s6">
      <title>Abbreviations</title>
      <p>EEHH: ethanolic extract of hypericum hookeranium</p>
      <p>HP: haloperidol</p>
      <p>I.P: intraperitoneal</p>
      <p>L-DOPA: levo dopa</p>
      <p>MPTP: 1-methyl-4-phenyl-1,2,3,6-tetrahydroxypyridine</p>
      <p>NAD: nicotinamide adenine dinucleotide</p>
      <p>PD: Parkinson's disease</p>
      <p>PO: per oral</p>
    </sec>
    <sec id="s7">
      <title>Author contribution</title>
      <p>Atif Saeed, Arsalan Ali and Muhammad Yousaf performed lab work and behavioral testing. Awais Ali Zaidi give the concept, designed experiment and supervised the project. Lubna Shakir helped in data acquisition and experiment conditions optimization Mahtab Ahmad Khan analyzed data and gave final approval of the project</p>
    </sec>
  </body>
  <back>
    <ref-list>
      <title>References</title>
      <ref id="ref1">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>A.</surname>
              <given-names>Aartsma-Rus</given-names>
            </name>
            <name>
              <surname>M.</surname>
              <given-names>van Putten</given-names>
            </name>
          </person-group>
          <article-title>Assessing functional performance in the mdx mouse model</article-title>
          <source>JoVE (Journal of Visualized Experiments)</source>
          <year>2014</year>
          <fpage>e51303</fpage>
          <lpage>e51303</lpage>
        </element-citation>
      </ref>
      <ref id="ref2">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>H.</surname>
              <given-names>Bernheimer</given-names>
            </name>
            <name>
              <surname>W.</surname>
              <given-names>Birkmayer</given-names>
            </name>
            <name>
              <surname>O.</surname>
              <given-names>Hornykiewicz</given-names>
            </name>
            <name>
              <surname>K.</surname>
              <given-names>Jellinger</given-names>
            </name>
            <name>
              <surname>F.</surname>
              <given-names>Seitelberger</given-names>
            </name>
          </person-group>
          <article-title>Brain dopamine and the syndromes of Parkinson and Huntington Clinical, morphological and neurochemical correlations</article-title>
          <source>Journal of the neurological sciences</source>
          <year>1973</year>
          <volume>20</volume>
          <fpage>415</fpage>
          <lpage>455</lpage>
        </element-citation>
      </ref>
      <ref id="ref3">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>M.E.</surname>
              <given-names>Burger</given-names>
            </name>
            <name>
              <surname>R.</surname>
              <given-names>Fachinetto</given-names>
            </name>
            <name>
              <surname>G.</surname>
              <given-names>Zeni</given-names>
            </name>
            <name>
              <surname>J.B.</surname>
              <given-names>Rocha</given-names>
            </name>
          </person-group>
          <article-title>Ebselen  attenuates haloperidol-induced  orofacial  dyskinesia  and  oxidative  stress  in  rat  brain</article-title>
          <source>Pharmacology Biochemistry and Behavior</source>
          <year>2005</year>
          <volume>81</volume>
          <fpage>608</fpage>
          <lpage>615</lpage>
        </element-citation>
      </ref>
      <ref id="ref4">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>A.</surname>
              <given-names>Chauhan</given-names>
            </name>
            <name>
              <surname>V.</surname>
              <given-names>Chauhan</given-names>
            </name>
            <name>
              <surname>W.T.</surname>
              <given-names>Brown</given-names>
            </name>
            <name>
              <surname>I.</surname>
              <given-names>Cohen</given-names>
            </name>
          </person-group>
          <article-title>Oxidative stress in autism: Increased  lipid  peroxidation  and  reduced  serum  levels  of  ceruloplasmin  and transferrin-the antioxidant proteins</article-title>
          <source>Life sciences</source>
          <year>2004</year>
          <volume>75</volume>
          <fpage>2539</fpage>
          <lpage>2549</lpage>
        </element-citation>
      </ref>
      <ref id="ref5">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>I.</surname>
              <given-names>Creese</given-names>
            </name>
            <name>
              <surname>D.R.</surname>
              <given-names>Burt</given-names>
            </name>
            <name>
              <surname>S.H.</surname>
              <given-names>Snyder</given-names>
            </name>
          </person-group>
          <article-title>Dopamine receptor binding predicts clinical  and  pharmacological  potencies  of  antischizophrenic  drugs</article-title>
          <source>science</source>
          <year>1976</year>
          <volume>192</volume>
          <fpage>481</fpage>
          <lpage>483</lpage>
        </element-citation>
      </ref>
      <ref id="ref6">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>A.M.</surname>
              <given-names>Elkashef</given-names>
            </name>
            <name>
              <surname>R.J.</surname>
              <given-names>Wyatt</given-names>
            </name>
          </person-group>
          <article-title>Tardive dyskinesia: possible involvement of free radicals and treatment with vitamin E</article-title>
          <source>Schizophrenia bulletin</source>
          <year>1999</year>
          <volume>25</volume>
          <fpage>731</fpage>
          <lpage>740</lpage>
        </element-citation>
      </ref>
      <ref id="ref7">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>P.O.</surname>
              <given-names>Fernagut</given-names>
            </name>
            <name>
              <surname>E.</surname>
              <given-names>Diguet</given-names>
            </name>
            <name>
              <surname>B.</surname>
              <given-names>Labattu</given-names>
            </name>
            <name>
              <surname>F.</surname>
              <given-names>Tison</given-names>
            </name>
          </person-group>
          <article-title>A simple method to measure stride length as an index of nigrostriatal dysfunction in mice</article-title>
          <source>Journal of neuroscience methods</source>
          <year>2002</year>
          <volume>113</volume>
          <fpage>123</fpage>
          <lpage>130</lpage>
        </element-citation>
      </ref>
      <ref id="ref8">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>A.</surname>
              <given-names>Gurakar</given-names>
            </name>
            <name>
              <surname>J.M.</surname>
              <given-names>Hoeg</given-names>
            </name>
            <name>
              <surname>G.</surname>
              <given-names>Kostner</given-names>
            </name>
            <name>
              <surname>N.M.</surname>
              <given-names>Papadopoulos</given-names>
            </name>
            <name>
              <surname>H.B.</surname>
              <given-names>Brewer</given-names>
            </name>
          </person-group>
          <article-title>Levels of lipoprotein Lp (a) decline with neomycin and niacin treatment</article-title>
          <source>Atherosclerosis</source>
          <year>1985</year>
          <volume>57</volume>
          <fpage>293</fpage>
          <lpage>301</lpage>
        </element-citation>
      </ref>
      <ref id="ref9">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>D.</surname>
              <given-names>Hirtz</given-names>
            </name>
            <name>
              <surname>D.</surname>
              <given-names>Thurman</given-names>
            </name>
            <name>
              <surname>K.</surname>
              <given-names>Gwinn-Hardy</given-names>
            </name>
            <name>
              <surname>M.</surname>
              <given-names>Mohamed</given-names>
            </name>
            <name>
              <surname>A.</surname>
              <given-names>Chaudhuri</given-names>
            </name>
            <name>
              <surname>R.</surname>
              <given-names>Zalutsky</given-names>
            </name>
          </person-group>
          <article-title>How common are the &#8220;common&#8221; neurologic disorders?</article-title>
          <source>Neurology</source>
          <year>2007</year>
          <volume>68</volume>
          <fpage>326</fpage>
          <lpage>337</lpage>
        </element-citation>
      </ref>
      <ref id="ref10">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>P.A.</surname>
              <given-names>Kempster</given-names>
            </name>
            <name>
              <surname>B.</surname>
              <given-names>Hurwitz</given-names>
            </name>
            <name>
              <surname>A.J.</surname>
              <given-names>Lees</given-names>
            </name>
          </person-group>
          <article-title>A new look at James Parkinson's Essay on the Shaking Palsy</article-title>
          <source>Neurology</source>
          <year>2007</year>
          <volume>69</volume>
          <fpage>482</fpage>
          <lpage>485</lpage>
        </element-citation>
      </ref>
      <ref id="ref11">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>T.J.</surname>
              <given-names>Klein</given-names>
            </name>
            <name>
              <surname>M.A.</surname>
              <given-names>Lewis</given-names>
            </name>
          </person-group>
          <article-title>A physical model of sensorimotor interactions during locomotion</article-title>
          <source>Journal of neural engineering</source>
          <year>2012</year>
          <volume>9</volume>
          <fpage>046011</fpage>
        </element-citation>
      </ref>
      <ref id="ref12">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>T.</surname>
              <given-names>Klockgether</given-names>
            </name>
          </person-group>
          <article-title>Parkinson&#8217;s disease: clinical aspects</article-title>
          <source>Cell and tissue research</source>
          <year>2004</year>
          <volume>318</volume>
          <fpage>115</fpage>
          <lpage>120</lpage>
        </element-citation>
      </ref>
      <ref id="ref13">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>T.</surname>
              <given-names>Kobayashi</given-names>
            </name>
            <name>
              <surname>T.</surname>
              <given-names>Araki</given-names>
            </name>
            <name>
              <surname>Y.</surname>
              <given-names>Itoyama</given-names>
            </name>
            <name>
              <surname>M.</surname>
              <given-names>Takeshita</given-names>
            </name>
            <name>
              <surname>T.</surname>
              <given-names>Ohta</given-names>
            </name>
            <name>
              <surname>Y.</surname>
              <given-names>Oshima</given-names>
            </name>
          </person-group>
          <article-title>Effects of  L-dopa  and  bromocriptine  on  haloperidol-induced  motor  deficits  in  mice</article-title>
          <source>Life sciences</source>
          <year>1997</year>
          <volume>61</volume>
          <fpage>2529</fpage>
          <lpage>2538</lpage>
        </element-citation>
      </ref>
      <ref id="ref14">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>S.</surname>
              <given-names>Manikandaselvi</given-names>
            </name>
            <name>
              <surname>R.</surname>
              <given-names>Mahalakshmi</given-names>
            </name>
            <name>
              <surname>R.</surname>
              <given-names>Thinagarbabu</given-names>
            </name>
            <name>
              <surname>A.</surname>
              <given-names>Angumeenal</given-names>
            </name>
          </person-group>
          <article-title>Neuroprotective activity of S-Allylcysteine on Haloperidol induced Parkinson&#8217;s disease in albino mice</article-title>
          <source>Int J Pharm Technol Res</source>
          <year>2012</year>
          <volume>4</volume>
          <fpage>669</fpage>
          <lpage>675</lpage>
        </element-citation>
      </ref>
      <ref id="ref15">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>J.</surname>
              <given-names>Molina</given-names>
            </name>
            <name>
              <surname>F.</surname>
              <given-names>Jim&#233;nez-Jim&#233;nez</given-names>
            </name>
            <name>
              <surname>J.</surname>
              <given-names>Navarro</given-names>
            </name>
            <name>
              <surname>C.</surname>
              <given-names>Vargas</given-names>
            </name>
            <name>
              <surname>P.</surname>
              <given-names>Gomez</given-names>
            </name>
            <name>
              <surname>J.</surname>
              <given-names>Benito-Le&#243;n</given-names>
            </name>
            <name>
              <surname>M.</surname>
              <given-names>Ort&#237;-Pareja</given-names>
            </name>
            <name>
              <surname>E.</surname>
              <given-names>Cisneros</given-names>
            </name>
            <name>
              <surname>J.</surname>
              <given-names>Arenas</given-names>
            </name>
          </person-group>
          <article-title>Cerebrospinal fluid nitrate levels in patients with Parkinson's disease</article-title>
          <source>Acta neurologica scandinavica</source>
          <year>1996</year>
          <volume>93</volume>
          <fpage>123</fpage>
          <lpage>126</lpage>
        </element-citation>
      </ref>
      <ref id="ref16">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>M.C.</surname>
              <given-names>Morris</given-names>
            </name>
            <name>
              <surname>D.A.</surname>
              <given-names>Evans</given-names>
            </name>
            <name>
              <surname>J.L.</surname>
              <given-names>Bienias</given-names>
            </name>
            <name>
              <surname>P.A.</surname>
              <given-names>Scherr</given-names>
            </name>
            <name>
              <surname>C.C.</surname>
              <given-names>Tangney</given-names>
            </name>
            <name>
              <surname>L.E.</surname>
              <given-names>Hebert</given-names>
            </name>
            <name>
              <surname>D.</surname>
              <given-names>Bennett</given-names>
            </name>
            <name>
              <surname>R.S.</surname>
              <given-names>Wilson</given-names>
            </name>
            <name>
              <surname>N.</surname>
              <given-names>Aggarwal</given-names>
            </name>
          </person-group>
          <article-title>Dietary niacin and the risk of  incident  Alzheimer&#8217;s disease and of cognitive decline</article-title>
          <source>Journal of</source>
          <year>2004</year>
          <volume>Neurology</volume>
          <fpage>Neurosurgery &amp; Psychiatry 75, 1093</fpage>
          <lpage>1099</lpage>
        </element-citation>
      </ref>
      <ref id="ref17">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>P.S.</surname>
              <given-names>Naidu</given-names>
            </name>
            <name>
              <surname>A.</surname>
              <given-names>Singh</given-names>
            </name>
            <name>
              <surname>S.K.</surname>
              <given-names>Kulkarni</given-names>
            </name>
          </person-group>
          <article-title>Quercetin, a bioflavonoid, attenuates haloperidol-induced orofacial dyskinesia</article-title>
          <source>Neuropharmacology</source>
          <year>2003</year>
          <volume>44</volume>
          <fpage>1100</fpage>
          <lpage>1106</lpage>
        </element-citation>
      </ref>
      <ref id="ref18">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>T.</surname>
              <given-names>Pavan</given-names>
            </name>
            <name>
              <surname>K.</surname>
              <given-names>Manasa</given-names>
            </name>
            <name>
              <surname>T.</surname>
              <given-names>Tamilanban</given-names>
            </name>
            <name>
              <surname>V.</surname>
              <given-names>Alagarsamy</given-names>
            </name>
          </person-group>
          <article-title>Effect of Methanolic extract of Canscora decussata on Haloperidol-Induced Motor deficits in Albino mice</article-title>
          <source>Int J Pharm Sci Rev Res</source>
          <year>2015</year>
          <volume>35</volume>
          <fpage>7</fpage>
          <lpage>11</lpage>
        </element-citation>
      </ref>
      <ref id="ref19">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>U.D.</surname>
              <given-names>Pongiya</given-names>
            </name>
            <name>
              <surname>B.M.</surname>
              <given-names>Kandanath</given-names>
            </name>
            <name>
              <surname>Y.R.</surname>
              <given-names>Rao</given-names>
            </name>
          </person-group>
          <article-title>Efficacy  of  hypericum hookerianum in reversing the symptoms of haloperidol induced tardive dyskenesia, catatonia and catalepsy in swiss albino mice-behavioural analysis report</article-title>
          <source>World Journal of Pharmacy And Pharmaceutical Sciences</source>
          <year>2014</year>
          <volume>3</volume>
          <fpage>1682</fpage>
          <lpage>1705</lpage>
        </element-citation>
      </ref>
      <ref id="ref20">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>M.</surname>
              <given-names>Rahman</given-names>
            </name>
            <name>
              <surname>S.</surname>
              <given-names>Muhammad</given-names>
            </name>
            <name>
              <surname>M.A.</surname>
              <given-names>Khan</given-names>
            </name>
            <name>
              <surname>H.</surname>
              <given-names>Chen</given-names>
            </name>
            <name>
              <surname>D.A.</surname>
              <given-names>Ridder</given-names>
            </name>
            <name>
              <surname>H.</surname>
              <given-names>Muller-Fielitz</given-names>
            </name>
            <name>
              <surname>B.</surname>
              <given-names>Pokorna</given-names>
            </name>
            <name>
              <surname>T.</surname>
              <given-names>Vollbrandt</given-names>
            </name>
            <name>
              <surname>I.</surname>
              <given-names>Stolting</given-names>
            </name>
            <name>
              <surname>R.</surname>
              <given-names>Nadrowitz</given-names>
            </name>
          </person-group>
          <article-title>The  beta-hydroxybutyrate receptor HCA2 activates a neuroprotective subset of macrophages</article-title>
          <source>Nature communications</source>
          <year>2014</year>
          <volume>5</volume>
          <fpage>3944</fpage>
        </element-citation>
      </ref>
      <ref id="ref21">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>B.</surname>
              <given-names>Scholtissen</given-names>
            </name>
            <name>
              <surname>F.</surname>
              <given-names>Verhey</given-names>
            </name>
            <name>
              <surname>H.</surname>
              <given-names>Steinbusch</given-names>
            </name>
            <name>
              <surname>A.</surname>
              <given-names>Leentjens</given-names>
            </name>
          </person-group>
          <article-title>Serotonergic mechanisms in Parkinson&#8217;s disease: opposing results from preclinical and clinical data</article-title>
          <source>Journal of neural transmission</source>
          <year>2006</year>
          <volume>113</volume>
          <fpage>59</fpage>
          <lpage>73</lpage>
        </element-citation>
      </ref>
      <ref id="ref22">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>H.</surname>
              <given-names>Sheidaei</given-names>
            </name>
          </person-group>
          <article-title>Buspirone improves haloperidol-induced Parkinson disease in mice  through  5-HT1A  recaptors</article-title>
          <source>DARU:  Journal  of  Faculty  of</source>
          <year>2010</year>
          <volume>Pharmacy</volume>
          <fpage>Tehran University of Medical Sciences 18, 41</fpage>
        </element-citation>
      </ref>
      <ref id="ref23">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>S.</surname>
              <given-names>Wang</given-names>
            </name>
            <name>
              <surname>L.-f.</surname>
              <given-names>Hu</given-names>
            </name>
            <name>
              <surname>Y.</surname>
              <given-names>Yang</given-names>
            </name>
            <name>
              <surname>J.-h.</surname>
              <given-names>Ding</given-names>
            </name>
            <name>
              <surname>G.</surname>
              <given-names>Hu</given-names>
            </name>
          </person-group>
          <article-title>Studies of ATP-sensitive potassium channels on 6-hydroxydopamine and haloperidol rat models of Parkinson's disease:  implications  for  treating  Parkinson's  disease?</article-title>
          <source>Neuropharmacology</source>
          <year>2005</year>
          <volume>48</volume>
          <fpage>984</fpage>
          <lpage>992</lpage>
        </element-citation>
      </ref>
      <ref id="ref24">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>A.A.</surname>
              <given-names>Zaidi</given-names>
            </name>
            <name>
              <surname>T.A.</surname>
              <given-names>Khan</given-names>
            </name>
            <name>
              <surname>L.</surname>
              <given-names>Shakir</given-names>
            </name>
            <name>
              <surname>M.A.</surname>
              <given-names>Khan</given-names>
            </name>
            <name>
              <surname>M.</surname>
              <given-names>Yousaf</given-names>
            </name>
            <name>
              <surname>A.</surname>
              <given-names>Ali</given-names>
            </name>
          </person-group>
          <article-title>Evaluation of C. cassia Effectiveness in Behavioral Modulation of Haloperidol Induced Parkinson&#8217;s Disease (Mice Model)</article-title>
          <source>British Journal of Pharmaceutical Research</source>
          <year>2016a</year>
          <volume>6</volume>
          <fpage>1</fpage>
          <lpage>7</lpage>
        </element-citation>
      </ref>
      <ref id="ref25">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>A.A.</surname>
              <given-names>Zaidi</given-names>
            </name>
            <name>
              <surname>L.</surname>
              <given-names>Shakir</given-names>
            </name>
            <name>
              <surname>T.A.</surname>
              <given-names>Khan</given-names>
            </name>
            <name>
              <surname>M.A.</surname>
              <given-names>Khan</given-names>
            </name>
            <name>
              <surname>A.</surname>
              <given-names>Ali</given-names>
            </name>
            <name>
              <surname>A.U.</surname>
              <given-names>Rehman</given-names>
            </name>
          </person-group>
          <article-title>Haloperidol leads to torse de pointes in schizophrenic pool</article-title>
          <source>European Journal of Pharmaceutica And Medical Research</source>
          <year>2016b</year>
          <volume>3</volume>
          <fpage>84</fpage>
          <lpage>91</lpage>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>